Plenty of pharma execs have decried Democrats’ new drug pricing law. But few are willing to say they might delay treatments for cancer patients if it means making more money.
Plenty of pharma execs have decried Democrats’ new drug pricing law. But few are willing to say they might delay treatments for cancer patients if it means making more money.
The archived article is still locked. Capitalism wins again.